No Data
Hong Kong Stock Concept Tracking | The trend of domestic innovative drugs going abroad continues and is expected to become the main investment line in the pharmaceutical Sector (with related stocks attached).
Guoyuan stated that currently, innovative drugs in our country have entered the results realization stage, with significant R&D progress being catalyzed, and not affected by the trade war, expected to continue as the main investment line in the pharmaceutical Sector until 2025.
【Popular Industry】Global cancer drug research and development is accelerating, and China's forces are breaking through technology to restructure the industry landscape.
Jinwu Financial News | On May 13, the Hong Kong stock market saw a favorable trend for oncology-related concept stocks, with BEIGENE (06160) up 4.46%, CSTONE PHARMA-B (02616) up 2.80%, ASCLETIS-B (01672) up 2.65%, 3SBIO (01530) up 2.50%, HANSOH PHARMA (03692) up 2.28%, UNITED LAB (03933) up 2.03%, and CSPC PHARMA (01093) up 0.55%. This round of increase reflects not only the market's positive expectations for the research and development results of innovative drug companies but also reveals the dynamics in the Global oncology treatment field.
CStone Pharmaceuticals' (HKG:2616) Last Week's 14% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake
【Brokerage Focus】CITIC SEC: The performance disparity in the Medical industry is accelerating, and policy trends are clear.
Jinwu Financial News | CITIC SEC stated that in 2024, the overall revenue of medical listed companies under the CITIC SEC industry classification will decrease by 0.62% year-on-year, with a net income attributable to the parent company declining by 8.48%. Both revenue and profit experience negative growth, while indicators such as gross margin, net margin, and Cash / Money Market / revenue have seen a decline compared to 2022 and 2023. In Q1 2025, the overall revenue of medical listed companies will decrease by 4.56% year-on-year, with a net income attributable to the parent company declining by 11.28%, putting pressure on performance. Although negative growth is still observed in the overall healthcare industry's performance for 2024 and Q1 2025, various subsidiary sectors are...
Directly addressing AACR 2025 | CStone Pharmaceuticals (02616) announced multiple preclinical research results for CS2011 (EGFR/HER3 bispecific antibody).
CStone Pharmaceutical announced the results of multiple preclinical studies, including CS2011.
CSTONE PHARMA-B: 2024 ANNUAL REPORT
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
